Pediatric infratentorial ependymoma
disease diseaseOn this page
Also known as childhood infratentorial ependymomainfratentorial ependymoma
Summary
Pediatric infratentorial ependymoma (MONDO:0004248) is a disease and 14 clinical trials. Top therapeutic interventions include edotreotide gallium ga-68, irinotecan hydrochloride, and romidepsin. A subtype of childhood infratentorial neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pediatric infratentorial ependymoma |
| Mondo ID | MONDO:0004248 |
| DOID | DOID:7501 |
| NCIT | C9041 |
| UMLS | C0278599 |
| MedGen | 82949 |
| GARD | 0023898 |
| Is cancer (heuristic) | no |
Also known as: childhood infratentorial ependymoma · infratentorial ependymoma · pediatric infratentorial ependymoma
Disease family
This is a subtype of childhood infratentorial neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › childhood neoplasm › childhood infratentorial neoplasm › pediatric infratentorial ependymoma
Related subtypes (3): childhood brain stem neoplasm, childhood cerebellar neoplasm, pediatric infratentorial ependymoblastoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 9 |
| Not specified | 3 |
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00004078 | PHASE2 | COMPLETED | Irinotecan in Treating Children With Refractory Solid Tumors |
| NCT01462695 | PHASE2 | COMPLETED | Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma |
| NCT00052780 | PHASE1 | COMPLETED | Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors |
| NCT00053963 | PHASE1 | COMPLETED | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia |
| NCT00063973 | PHASE1 | COMPLETED | Cilengitide in Treating Children With Refractory Primary Brain Tumors |
| NCT00100880 | PHASE1 | COMPLETED | Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors |
| NCT00326664 | PHASE1 | COMPLETED | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors |
| NCT00363272 | PHASE1 | COMPLETED | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma |
| NCT00946335 | PHASE1 | COMPLETED | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors |
| NCT01076530 | PHASE1 | COMPLETED | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors |
| NCT01088763 | PHASE1 | TERMINATED | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
| NCT00919750 | Not specified | COMPLETED | Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors |
| NCT01407744 | Not specified | COMPLETED | Study of Tumor Samples From Patients With Ependymoma Treated on the Children’s Oncology Group ACNS0121 Trial |
| NCT02194452 | Not specified | WITHDRAWN | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| EDOTREOTIDE GALLIUM GA-68 | 4 | 1 |
| IRINOTECAN HYDROCHLORIDE | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| VELIPARIB | 3 | 2 |
| 6-O-BENZYLGUANINE | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| CILENGITIDE | 3 | 1 |
| ISPINESIB | 2 | 1 |
| CHEMBL541887 | 0 | 1 |
| CHEMBL3109278 | 0 | 1 |
| CHEMBL4066465 | 0 | 1 |
| CHEMBL2326523 | 0 | 1 |